

Funding Agency	Funding Opportunity	Solicitation Link	Topics	Due Date	Budget
Biomedical Advanced Research and Development Authority (BARDA)	BARDA BAA	https://beta.sam.gov/opp/d1b6e601426e4e4c943235babdd4133a/view	Products to diagnose, prevent or treat novel coronavirus infections	Rolling, through 10/31/2020	Unlimited
Biomedical Advanced Research and Development Authority (BARDA)	Division of Research, Innovation & Ventures (DRIVE) BAA	https://beta.sam.gov/opp/b4f7923443a448218d369209723141c5/view	Diagnostic assays, screening and model development, vaccines, advanced manufacturing.	Abstract submissions due by 5PM ET on 10/31/2020.	\$750,000
Biomedical Advanced Research and Development Authority (BARDA)	CoronaWatch				
National Institutes of Health (NIH)	NIH Director's Emergency Transformative Research Awards (R01 Clinical Trial Optional)	https://grants.nih.gov/grants/guide/rfa-files/RFA-RM-20-020.html	Any area of research relevant to the prevention of, preparation for, or response to coronavirus SARS-CoV-2, including behavioral/social science research, research on health disparities, novel therapeutics, and other related topics	9/30/2020 (opens 8/30/2020)	Not limited, but must be commensurate with the scope of the proposed research

Funding Agency	Funding Opportunity	Solicitation Link	Topics	Due Date	Budget
National Institutes of Health (NIH)	NIA Multi-site COVID-19 Related Clinical Trial	http://grants.nih.gov/grants/guide/pa-files/PAR-20-234.html	<p>Efficacy and safety of interventions that target aging-related biological mechanisms that may influence risk or severity of COVID-19 infection among at-risk older adults</p> <p>Efficacy and safety of preventive and treatment interventions in older patients with differing comorbid conditions that make them especially vulnerable to adverse outcomes of COVID-19 infection</p> <p>Effectiveness of health and/or custodial care practices to reduce transmission risk or improve outcomes of COVID-19 infection in nursing homes or other residential settings serving at-risk older persons, including the development and testing of infection control training procedures for healthcare workers</p> <p>Rapid pragmatic trials in (at least two) health systems, nursing homes, or adult living facilities, ensuring replication across large pragmatic trial sites and leveraging electronic health records to promote quality improvement in physician, hospital, palliative care, and hospice practices to improve outcomes for older patients with COVID-19, especially those with cognitive impairment, Alzheimer’s disease or Alzheimer’s disease-related dementias (AD/ADRD), or underlying</p>	9/1/2020, 10/1/2020, 11/2/2020, 12/1/2020, 1/4/2021, and 2/1/2021	Not limited
National Institutes of Health (NIH)	R01 Grants for Community Interventions - Community Interventions to Address the Consequences of the COVID-19 Pandemic among Health Disparity and Vulnerable Populations (R01- Clinical Trial Optional)	http://grants.nih.gov/grants/guide/pa-files/PAR-20-237.html	Research topics of interest relate to the behavioral, social, socioeconomic and health impacts of the COVID-19 pandemic with respect to health disparity and vulnerable populations. See the solicitation for a list of example topics.	8/28/2020 and 12/1/2020	\$500,000 in direct costs

Funding Agency	Funding Opportunity	Solicitation Link	Topics	Due Date	Budget
	Digital Healthcare Interventions to Address the Secondary Health Effects Related to Social, Behavioral, and Economic Impact of COVID-19 (R01 – Clinical Trial Optional)>	https://grants.nih.gov/grants/guide/pa-files/PAR-20-243.html	See the solicitation for a detailed description of relevant topics and high-priority study areas	12/2/2020, and 3/2/2021	\$750,000 in direct cost per year for up to 3 years
National Institutes of Health (NIH)	Notice of Special Interest (NOSI): Simulation Modeling and Systems Science to Address Health Disparities	https://grants.nih.gov/grants/guide/notice-files/NOT-MD-20-025.html	<p>The specific areas of interest of each participating institute or center are listed in the NOSI (see link), but in general, proposals are solicited for projects addressing the following research objectives:</p> <p>Foster trans-disciplinary partnerships and collaborations in understanding the etiology and causal pathways of health disparities using simulation modeling and systems science (SMSS)</p> <p>Use SMSS to identify modifiable barriers and cost-effective factors to reduce and eventually eliminate health disparities</p> <p>Use SMSS to improve patient safety and reduce medical errors for populations affected by health disparities</p> <p>Use SMSS to assess and predict the spread and consequences of pandemics (e.g., SARS-CoV-2) and the effectiveness of interventions in populations affected by health disparities</p> <p>Provide evidence-based simulation or prediction of the impact of effective or ineffective health disparities interventions delivered in real-world settings</p> <p>Promote big data harmonization and novel analytic methods in SMSS to address minority</p>	Standard RO1 due	Not limited

Funding Agency	Funding Opportunity	Solicitation Link	Topics	Due Date	Budget
National Institutes of Health (NIH)	Multi-Institute NOSI: Community Interventions NOSI: Competitive and Administrative Supplements for Community Interventions to Reduce the Impact of COVID-19 on Health Disparity and Other Vulnerable Populations	https://grants.nih.gov/grants/guide/notice-files/not-md-20-022.html	Mitigation strategies in populations who experience health disparities and other vulnerable groups Evaluating community interventions (existing, new, or adapted) to ameliorate the negative health impacts of the COVID-19 pandemic in populations with health disparities and other vulnerable populations	Applications are accepted on a rolling basis until 12/15/2020.	\$250,000 in direct costs
National Institutes of Health (NIH)	Multi-Institute NOSI: Digital Interventions NOSI: Digital Healthcare Interventions to Address the Secondary Health Effects Related to Social, Behavioral, and Economic Impact of COVID-19	https://grants.nih.gov/grants/guide/notice-files/not-mh-20-053.html	Strategies to increase the reach, access, engagement, efficiency, quality and sustainability of existing evidence-based or validated digital health interventions to address healthcare needs of health disparate and other vulnerable populations, including screening, prevention, self-management, wellness behaviors and treatment both during and following the pandemic Studies to evaluate the near-term impact of replacement (or substitution) of face to face services with digital health as a result of the pandemic to address health disparities and vulnerable population needs	Applications are accepted on a rolling basis until 12/15/2020.	\$200,000 in direct costs
National Institutes of Health (NIH)	Multi-Institute NOSI: COVID-19 and Down Syndrome				
National Institutes of Health (NIH)	NIA/NIMH - NOSI: Administrative Supplements and Revision Supplements on Coronavirus Disease 2019 (COVID-19)	https://grants.nih.gov/grants/guide/pa-files/pa-18-935.html	NIA – Mission critical areas as they relate to the COVID-19 pandemic. NIMH – Applications addressing care for new or worsening mental health needs and/or suicide risk in midlife and older age adults will be seen as a high priority.	Rolling until 5/1/2021	Limited to no more than that amount of the current parent award.

Funding Agency	Funding Opportunity	Solicitation Link	Topics	Due Date	Budget
National Institutes of Health (NIH)	National Heart, Lung, Blood Institute (NHLBI) - NOSI: Availability of Emergency Competitive Revisions on Coronavirus Disease 2019 (COVID-19) for Currently Active NHLBI Phase I-III Clinical Trials	https://grants.nih.gov/grants/guide/notice-files/NOT-HL-20-782.html	Safety and efficacy of interventions for primary prevention and/or treatment of COVID-19, associated clinical phenotypes, and surrogate outcomes, relevant to heart, lung, and blood (HLB) diseases	10/5/2020	Not specified
National Institutes of Health (NIH)	National Heart, Lung, Blood Institute (NHLBI) NOSI: Administrative Supplements and Revision Supplements on Coronavirus Disease 2019 (COVID-19)	https://grants.nih.gov/grants/guide/notice-files/NOT-HL-20-757.html	COVID-19 related research including host response, associations with heart, lung, and blood (HLB) diseases, potential impacts on transfusion safety, and clinical outcomes of infected individuals.	Rolling, through 10/5/2020	Not specified
National Institutes of Health (NIH)	National Institute of Allergy and Infectious Diseases (NIAID) - Emergency Awards: Rapid Investigation of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19)	https://grants.nih.gov/grants/guide/notice-files/NOT-AI-20-065.html	Proposals are sought to evaluate SARS-CoV-2 candidate vaccines, non-vaccine biomedical prevention of SARS-CoV-2 infection and/or COVID-19, and therapeutic approaches to treat COVID-19. Please note, studies evaluating behavioral interventions (e.g., impact of face masks, hand-washing, social distancing) and those focused on disinfecting surfaces and equipment are not responsive and will not be considered for this NOSI initiative	Applications will be accepted once a month from 09/14/2020 through 09/14/2021	Not limited
National Institutes of Health (NIH)	National Institute of General Medical Sciences (NIGMS) - NOSI: Urgent Competitive Revisions for Research on Coronavirus Disease 2019 (COVID-19) and the Causative Virus SARS-CoV-2		Predictive models for the spread of SARS-CoV-2 and other related infectious agents (all relevant grants). Repurposing or modification of diagnostic tools currently under development to enable rapid detection of SARS-CoV-2 infection; rapid development of potential therapeutic agents for COVID-19 (SBIR/STTR grants only).	Rolling, through 2/6/2021	Not specified

Funding Agency	Funding Opportunity	Solicitation Link	Topics	Due Date	Budget
National Institutes of Health (NIH)	National Center for Advancing Translational Sciences (NCATS) - Urgent Phase I/II Clinical Trials to Repurpose Existing Therapeutic Agents to Treat COVID-19 Sequelae (U01 Clinical Trial Required)		Clinical trials of existing therapeutic agents for treating COVID-19	Applications are accepted on a rolling basis until 1/24/2020.	\$3,000,000 in direct costs per year for up to 3 years
National Institutes of Health (NIH)	National Institute of Drug Abuse (NIDA) - NOSI: Administrative Supplements and Urgent Competitive Revisions for Research on the 2019 Novel Coronavirus		NIDA is interested in research collecting and examining data on the risks and outcomes for COVID-19 infection in individuals suffering from substance use disorders.	Rolling, through 3/31/2021	Maximum of \$100,000 direct costs per year for 2 years. Higher budgets may be considered with justification.


Funding Agency	Funding Opportunity	Solicitation Link	Topics	Due Date	Budget
National Institutes of Health (NIH)	National Institute on Deafness and Other Communication Disorders (NIDCD) - NOSI: NIDCD is Interested in Supporting Research on the Impact of COVID-19 on Mission Specific Sensory and Communication Disorders		<p>Topics include, but are not limited to, the following:</p> <p>The effects of prolonged oral intubation on laryngeal function and voice production</p> <p>Short-term and long-term effects of COVID-19 on the auditory, vestibular, or olfactory systems</p> <p>The prevalence, onset, and resolution of acquired deficits (i.e., HBTSVSL) among patients with COVID-19 across the lifespan and in association with various underlying genetic predispositions and health conditions</p> <p>The molecular mechanisms underlying chemosensory dysfunction due to SARS-CoV-2 infection</p> <p>The impact of stress/isolation on speech, language or fluency recovery/development in children or adults</p> <p>The impact of potential congenital transmission of maternal SARS-CoV-2 infection to the newborn in relation to the auditory, vestibular, olfactory, or vocal function and/or the impact on speech production or language acquisition</p> <p>Potential ototoxicity from therapeutics or vaccination related to COVID-19</p> <p>Worsening of communicative function because</p>	Various program-specific due dates on or after 10/5/2020	Varies by program

Funding Agency	Funding Opportunity	Solicitation Link	Topics	Due Date	Budget
National Institutes of Health (NIH)	National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) - Mechanistic Studies of the Interaction between SARS-CoV-2/COVID-19 and Diseases and Organ Systems of Interest to NIDDK (R01 Clinical Trial Optional)		The purpose of this Funding Opportunity Announcement (FOA) is to support basic and clinical mechanistic research on Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19) susceptibility, routes of infection, course of disease, morbidity and mortality in people with pre-existing diseases, or adverse acute or chronic outcomes in organs, tissues, and biological systems of specific interest to NIDDK. These include diabetes and other metabolic diseases, obesity, and endocrine, digestive, liver, pancreas, kidney, urological, and hematologic tissues and diseases.	12/16/2020	\$250,000 in direct costs per year for up to 3 years
National Institutes of Health (NIH)	National Institute of Biomedical Imaging and Bioengineering (NIBIB) -		Rapid diagnostics, wearable/implantable sensors, digital health platforms, healthcare training platforms, robotic technologies to limit caregiver exposure, ventilators, and disinfectant technologies	Varies by NOSI	Varies by NOSI
National Institutes of Health (NIH)	Current Grantees NOSI - Notice of Special Interest (NOSI): Availability of Emergency Competitive Revision and Administrative Supplements on Biomedical Technologies for Coronavirus Disease 2019 (COVID-19)		https://grants.nih.gov/grants/guide/notice-files/NOT-EB-20-008.html		

Funding Agency	Funding Opportunity	Solicitation Link	Topics	Due Date	Budget
National Institutes of Health (NIH)	SBIR/STTR Applicants NOSI - Notice of Special Interest (NOSI): Small Business Research and Development of Biomedical Technologies for Coronavirus Disease 2019 (COVID-19)	https://grants.nih.gov/grants/guide/notice-files/NOT-EB-20-006.html			
National Institutes of Health (NIH)	All Other Applicants NOSI - Notice of Special Interest (NOSI): Development of Biomedical Technologies for Coronavirus Disease 2019 (COVID-19)	https://grants.nih.gov/grants/guide/notice-files/NOT-EB-20-007.html			
National Institutes of Health (NIH)	National Institute of Neurological Disorders and Stroke (NINDS) - NOSI: Availability of Urgent Competitive Revisions and Administrative Supplements for Research on Biological Effects of the 2019 Novel Coronavirus on the Nervous System		Biology, pathophysiology, prevention, diagnosis, sequelae, or treatment of the 2019 Novel Coronavirus	Applications accepted on a rolling basis until 4/14/2021	\$200,000 in direct costs
Office of Strategic Coordination (OSC)	Currently no opportunities available				
National Library of Medicine (NLM)	Currently no opportunities available				

Funding Agency	Funding Opportunity	Solicitation Link	Topics	Due Date	Budget
National Institute of Dental and Craniofacial Research (NIDCR)	NOSI: Availability of Urgent Competitive Revisions and Administrative Supplements for Coronavirus Disease 2019 (COVID-19) Research within the Mission of NIDCR		Prevention of SARS-COV-2 transmission Improvements in the detection and diagnosis of COVID-19 Acquisition of a more robust understanding of SARS-CoV-2 pathogenesis Influence and interaction of sex (a biological variable) and gender (a social construct), race and ethnicity in relation to COVID-19 COVID-19 risk, prevention, and health outcomes	11/2/2020	\$150,000 in total direct costs
National Center for Complementary and Integrative Health (NCCIH)	No current opportunities				
NIH Office of the Director	Currently no opportunities available				
National Cancer Institute	No current opportunities				

Funding Agency	Funding Opportunity	Solicitation Link	Topics	Due Date	Budget
RADx-UP	RAX-UP - NOSI: Emergency Competitive Revisions for Social, Ethical, and Behavioral Implications (SEBI) Research on COVID-19 Testing among Underserved and/or Vulnerable Populations		<p>Topics of interest include but are not limited to:</p> <p>Which social, ethical and behavioral facilitators and barriers substantially influence decisions about whether and when to offer or seek COVID-19 testing?</p> <p>What strategies mitigate barriers, and increase access to and acceptability of testing and repeat testing?</p> <p>What are implications of both positive and negative COVID-19 diagnostic tests for underserved and/or vulnerable groups, and how do they influence testing decisions and downstream beliefs and behaviors?</p> <p>How are test results interpreted and used in these underserved and/or vulnerable communities?</p> <p>What are the risks and benefits of implementing new COVID-19 testing technologies in underserved and/or vulnerable communities from the perspectives of those populations?</p> <p>What population specific social, ethical, or behavioral factors should be addressed before deploying novel testing strategies?</p> <p>What factors should be addressed before</p>	9/8/2020	\$400,000 in direct costs
RADx-UP	RADx-UP - Emergency Awards: RADx-rad Data Coordination Center (DCC) (U24 Clinical Trial Not Allowed)		Proposals are sought to establish the RADx-rad Data Coordination Center (DCC), which will provide overarching support and guidance to RADx-rad awardees in the following three areas: (1) Administrative Operations and Logistics, (2) Data Collection, Integration and Sharing, and (3) Data Management and Use.	Letter of intent due 8/31/2020; application due 9/30/2020	\$4 million in annual direct costs for up to 4 years

Funding Agency	Funding Opportunity	Solicitation Link	Topics	Due Date	Budget
RADx-UP	RADx-UP - Emergency Awards: Automatic Detection and Tracing of SARS-CoV-2 (U01 Clinical Trial Not Allowed)		Development of a platform that integrates biosensing with touchscreen or other digital devices to achieve detection and tracing of SARS-CoV-2 in real time. The use of aptamers to detect SARS-CoV-2 is of particular interest.	Letter of intent due 8/21/2020; applications due 9/15/2020	\$300,000 in direct costs per year for up to 2 years
RADx-UP	RADx-UP - Emergency Awards: RADx-RAD Multimodal COVID-19 surveillance methods for high risk clustered populations (R01 Clinical Trial Optional)		Applications are invited that translate a combination of digital surveillance modalities into platforms that can assist the professional staff of high-risk facilities in making clinically meaningful care recommendations for patients at risk of COVID-19 or other respiratory viruses.	Letter of intent due 8/30/2020; applications due 9/30/2020	Not limited

Funding Agency	Funding Opportunity	Solicitation Link	Topics	Due Date	Budget
RADx-UP	RADx-UP - Emergency Awards: Chemosensory Testing as a COVID-19 Screening Tool (U01 Clinical Trial Optional)		<p>Areas of interest include:</p> <p>Development and deployment of standardized and validated over-the-counter testing kits or tests that utilize common household items for remote, home-based screening through telemedicine for mildly to moderately affected individuals.</p> <p>Modification of existing test platforms (e.g., NIH Toolbox) to improve the efficiency of administration, data collection, and evaluation using mobile phone apps and telemedicine.</p> <p>Development of innovative chemosensory platforms that can be implemented for the testing of large, at-risk populations, for example, health care workers, pregnant women, and older adults and caretakers residing/working at nursing homes and long-term care facilities.</p> <p>Establishment of appropriate odorants, optimal odorant concentrations, and standardized delivery systems and protocols for the development of onsite, group testing stations for those working or living in high-density, high-risk environments.</p> <p>Analysis of test results to determine the specificity of chemosensory testing with</p>	9/15/2020	\$750,000 in total direct costs


Funding Agency	Funding Opportunity	Solicitation Link	Topics	Due Date	Budget
RADx-UP	RADx-UP - Emergency Awards RADx-RAD: Novel Biosensing for Screening, Diagnosis and Monitoring of COVID-19 From Skin and The Oral Cavity (Fast-Track STTR Clinical Trial Not Allowed)		Biosensing and detection technologies submitted to this initiative should provide associations between biomarkers emanating from skin or the oral cavity to patients with symptomatic and asymptomatic COVID-19. Leveraging the accessibility of human skin and the oral cavity, this FOA seeks 1) to advance novel biosensing technologies that are innovative, safe, and effective, and 2) to implement such technologies into devices with integrated artificial intelligent (AI) systems for the detection, diagnosis, prediction, prognosis and monitoring of COVID-19 in clinical, community and everyday settings. Skin biosensing designs must target detection of volatile organic compounds (VOCs, i.e. scents or odors) emanating from skin in a passive and noninvasive manner for use at point of care. In addition to VOCs, oral biosensing technologies may target a wealth of biological, chemical and physical biosignatures representative of SARS-CoV-2 virus and/or COVID-19 disease sampled from exhaled breath/droplets, saliva, and tissues in the oral cavity using a variety of detection schemes.	Application due 9/18/2020	\$256,580 for Phase I and \$1,710,531 for Phase II

Funding Agency	Funding Opportunity	Solicitation Link	Topics	Due Date	Budget
RADx-UP	RADx-UP - Emergency Awards: RADx-rad Wastewater Detection of SARS-COV-2 (COVID-19) (U01 – Clinical Trials Not Allowed)>		<p>Funding Opportunity Purpose</p> <p>The National Institutes of Health (NIH) is issuing this funding opportunity announcement (FOA) in response to the declared public health emergency issued by the Secretary, Department of Health and Human Services (DHHS), for the 2019 Novel Coronavirus (COVID-19). This emergency FOA provides an expedited funding mechanism as part of the Rapid Acceleration of Diagnostics-Radical (RADx-rad) initiative. As one of the programs within the NIH Rapid Acceleration of Diagnostics-Radical (RADx-rad) program the RADx-rad Wastewater Detection of SARS-COV-2 (COVID-19) FOA will support wastewater-based testing (WBT) surveillance which can provide detailed mapping of the extent and spread of COVID-19. Wastewater testing has been shown to be orders of magnitude cheaper and faster than clinical screening, albeit serving as a complementary approach rather than substituting individual-level testing and screening. The purpose of this FOA is to solicit cooperative agreements both for field studies and for small business research and development projects in the field of WBT, to address topics such as: investigation and</p>	Application due 9/15/2020	\$2,000,000 in direct costs per year for up to 2 years
RADx-UP	RADx-UP - Emergency Awards RADx-RAD: Novel Biosensing for Screening, Diagnosis and Monitoring of COVID-19 From Skin and The Oral Cavity (R44 Clinical Trial Not Allowed)		Portable devices for COVID-19 diagnosis using volatile organic compound detection methods	Application due 9/18/2020	\$1,710,531 in total costs (unless qualifying for a budget waiver)

Funding Agency	Funding Opportunity	Solicitation Link	Topics	Due Date	Budget
RADx-UP	RADx-UP - Emergency Awards: Exosome-based Non-traditional Technologies Towards Multi-Parametric and Integrated Approaches for SARS-CoV-2 (U18 Clinical Trial Not Allowed)		SARS-CoV-2 detection via single-vesicle or exosome technologies	Application due 9/18/2020	Not limited
RADx-UP	RADx-UP - Emergency Awards RADx-RAD: Screening for COVID-19 by Electronic-Nose Technology (SCENT) (U18 Clinical Trial Not Allowed)		Development of a sensing device that can associate VOC patterns with symptomatic and asymptomatic COVID-19 patients and actively detect VOCs from skin and oral cavities of COVID-19 patients without being invasive or affecting the integrity of the skin and oral cavity. For VOC monitoring, the sensing device can utilize Electronic-nose (E-nose) technology or Gas Chromatography (GC). This FOA seeks to advance novel biosensing technologies that use integrated artificial intelligence, pattern recognition and machine learning systems that would make it possible to detect, diagnose, predict, and monitor COVID-19 in clinical, community and everyday settings.	due 9/18/2020	Not limited
RADx-UP	RADx-UP - Emergency Awards: RADx-rad Predicting Viral-Associated Inflammatory Disease Severity in Children with Laboratory Diagnostics and Artificial Intelligence (PreVAIL kids) (R61/R33 Clinical Trial Optional)		Rapid diagnosis and characterization of the spectrum of MIS-C associated with SARS-CoV-2 Accurate risk-stratification and prediction of severe disease (MIS-C) outcomes along the spectrum of SARS-CoV-2 exposure and/or infection and throughout the course of illness	Letter of intent due 8/31/2020; application due 9/30/2020	\$500,000 in direct costs per year in the R61 phase and \$1,000,000 in direct costs per year in the R33 phase
Frederick National Laboratories	No current opportunities				

Funding Agency	Funding Opportunity	Solicitation Link	Topics	Due Date	Budget
National Science Foundation (NSF)	Ecology and Evolution of Infectious Diseases (EEID)	https://www.nsf.gov/pubs/2019/nsf19592/nsf19592.htm		Deadline 11/18/2020	\$24M total to 10 grants
Department of Defense (DOD)	Defense Logistics Agency - Currently no opportunities available				
US Department of Agriculture (USDA)	National Institute of Food and Agriculture (NIFA) - In response to the current need for more COVID-19 information, certain NIFA programs will allow submission of COVID-19 relevant projects outside of their normal deadlines.	https://nifa.usda.gov/funding-opportunity/agriculture-and-food-research-initiative-foundational-applied-science-program	Focus areas of interest include, but are not limited to the following: Animal Nutrition, Growth and Lactation (A1231) Critical Agricultural Research and Extension (CARE) (A1701) Diseases of Agricultural Animals (A1221) Food Safety and Defense (A1332) Foundational Knowledge of Plant Products (A1103) Economics, Markets, and Trade (A1641)	Varies by Program	\$1,000,000
US Department of Agriculture (USDA)	Distance Learning and Telemedicine (DLT) Grants No current opportunities				
Department of Homeland Security	Innovative Commercial Products in Support of Coronavirus (COVID-19) Response – Commercial Solutions Opening Pilot Program (CSOP)	https://beta.sam.gov/api/prod/opps/v3/opportunities/resources/files/5bfc6fa5215342b6804558d0036ad4c2/download?api_key=null&token=	Proposed innovative commercial products may be, but are not limited to, products that: Supplement shortages and/or emerging needs for personal protective equipment Enhance or expedite screening capabilities Enhance or expedite facility cleaning capabilities Extend testing capabilities Utilize technology to support the COVID-19 response Convert existing production and logistics operations to support the COVID-19 response.	Proposals are accepted and considered on a rolling basis until 8/31/2020	Dependent on the contract

Funding Agency	Funding Opportunity	Solicitation Link	Topics	Due Date	Budget
Other US Funding Sources	Schmidt Futures - The Futures Forum on Learning: Tools Competition		<p>Solutions should aim to address one of the problem areas:</p> <ul style="list-style-type: none"> Increase the number of students who are reading by 3rd grade Increase the number of students on track in middle-school math Expand the number of students gaining data and computer science skills in high school Driving more students into college through academic and nonacademic supports Another pressing learning goal identified by the team that is related to COVID-19 	One-page concept description due 9/18/2020; detailed proposal due 10/26/2020	Applicants will request an award on one of three tracks: \$25,000 and under, \$25,000-\$100,000, and \$100,000-\$250,000
XPRIZE Foundation	XPRIZE Rapid Covid Testing		<p>The XPRIZE Foundation describes the competition as follows: "The winning teams will develop COVID-19 tests that are radically affordable compared to what's currently available on the market. For about the price of a latte, the tests will be equal to (or better than) commercial offerings at measuring sensitivity, specificity, and limit of detection, with a maximum turnaround time of 12-hours from sample to result. The winning teams will also be able to successfully deploy and conduct a minimum of 500 tests per week at a live testing site within 60 days, and have the potential to scale their solutions to thousands of tests per week."</p>	8/31/2020	The competition has a prize purse of \$5,000,000.
Pennsylvania Department of Community and Economic Development	No Current Opportunities				

Funding Agency	Funding Opportunity	Solicitation Link	Topics	Due Date	Budget
Wellcome, Bill & Melinda Gates Foundation, and Mastercard		https://www.gatesfoundation.org/Media-Center/Press-Releases/2020/03/COVID-19-Therapeutics-Accelerator	<p>The Accelerator is seeking partners for the following activities:</p> <ul style="list-style-type: none"> Identifying candidate compounds by testing approved drugs for activity against COVID-19, screening libraries of compounds with confirmed safety data, and considering new investigational compounds and monoclonal antibodies. Developing drugs or monoclonal antibodies that pass initial screening. Scaling up production and commercialization of successful drugs and monoclonal antibodies. 	Not Specified	Not Specified; Total Program Budget – \$125,000,000
National Institute of Standards and Technology (NIST)	NIST Manufacturing USA National Emergency Assistance Program	https://www.grants.gov/web/grants/search-grants.html?keywords=2020-NIST-MFGUSA-NEAP-01	<p>Projects should focus on responding to the COVID-19 pandemic. Projects may include medical countermeasures; non-medical countermeasures; leveraging institute capabilities to strengthen state and community resilience; grants to companies and technical support to accelerate productions of critical materials, equipment, and supplies; creation of additional production facilities; technology roadmapping for pandemic response and recovery; reshoring the manufacture of critical conventional drugs and ensuring supply chain for critical materials related to pandemic response; or workforce development and training for a skilled advanced manufacturing workforce.</p>	Rolling	\$250,000 – \$10 million
Coalition for Epidemic Preparedness Innovation (CEPI)	Achieving an unprecedented acceleration of vaccine development and global manufacturing capacity to prevent COVID-19		Development of a COVID-19 vaccine for large-scale production	Applications accepted on a rolling basis until at least 6/30/2020	Not Specified

Funding Agency	Funding Opportunity	Solicitation Link	Topics	Due Date	Budget
Massachusetts Institute of Technology (MIT)	No Current Opportunities				
California Institute for Regenerative Medicine	Special Call for COVID-19 Projects – Partnership Opportunities in Support of Discovery, Translational and Clinical Trial Stage Activities	https://www.cirm.ca.gov/sites/default/files/files/funding_page/COVID19-SA_0.pdf	Cell-based COVID-19 therapies that use, target, or are manufactured using stem or progenitor cells Gene therapies for COVID-19 that are intended to replace, regenerate, or repair the function of aged, diseased, damaged, or defective cells, tissues, and/or organs	Biweekly on an ongoing basis	\$150,000 – \$750,000 depending upon product stage
Amazon Web Services (AWS) Diagnostic Development Initiative (DDI)	No current opportunities				
Fast Grants	Fast Grants are available exclusively to PIs at academic institutions already working on COVID-19 related projects that could help with the pandemic within the next six months.	https://fastgrants.org/	All COVID-19 related science	Rolling, award decisions made in 48 hours.	\$10,000 – \$500,000
Patient-Centered Outcomes Research Institute (PCORI)	PCORI is requesting enhancements to existing Research Projects and Engagement Awards. COVID-19-Related Enhancements to Existing PCORI-Funded Research Projects COVID-19-Related Enhancements to Existing PCORI-Funded Engagement Awards		Modest additions to existing aims as they relate to COVID-19 or new aims designed to produce useful knowledge related to COVID-19 and the original award. Taking advantage of natural experiments in health system, state, and provider responses is strongly encouraged.	Rolling submissions	\$500,000 for Research Projects; \$150,000 for Engagement Awards
Call for Code & IBM	No current opportunities				

Funding Agency	Funding Opportunity	Solicitation Link	Topics	Due Date	Budget
West Coast Consortium for Technology & Innovation in Pediatrics (CTIP)	West Coast Consortium for Technology & Innovation in Pediatrics (CTIP)		Pediatric medical device development or adaptation to manage the impact of COVID-19 on children	Accepting applications on a rolling basis	\$15,000
Robert Wood Johnson Foundation	No current opportunities				
Office of the Director of National Intelligence	No current opportunities				
International Opportunities - Brazil	Emergency Action Projects to Combat the Effects of Covid-19 – FAPERJ / SES Partnership – 2020		Genomics Pathophysiology of the disease Clinical aspects Diagnosis of the disease Epidemiology Virus-host interaction Development of diagnostic kits Disease control and coping strategies Innovative solutions to expand supplies of items such as masks, alcohol gel, and respirators	Applications are accepted on a rolling basis	Not specified
International Opportunities - Finep	No current opportunities				
International Opportunities - Canada - Genome Canada	No current opportunities				
National Research Council Canada	National Research Council Industrial Research Assistance Program (NRC IRAP)		Development of COVID-19 solutions for health care workers and public health officials	None; applicants directly contact an Industrial Technology Advisor at NRC	Not specified
Eureka (Multiple Participating Nations)	No current opportunities				
European Union	AMable Open Call for Solution Ideas (COVID-19)		Challenges will involve a lack of equipment, helpful tools, replacement parts or parts that enable additional functionality.	10/1/2020	€10,000 per challenge
The European Commission	No current opportunities				

Funding Agency	Funding Opportunity	Solicitation Link	Topics	Due Date	Budget
France - DIM ELICIT	Special call for proposals: Development of innovative technologies & methods to fight SARS-CoV-2		<p>The technologies targeted in this call must belong to at least one core technology and one end-user application from the following lists:</p> <p>Core technologies:</p> <ul style="list-style-type: none"> Microfluidics Biophotonic and waves Image analysis and Big Data <p>End-user applications:</p> <ul style="list-style-type: none"> Single cell/Single molecule Organ-on-a-chip Technologies for in vivo biology High-tech, low-cost technologies 	Applications are accepted on a rolling basis	€15k for running and/or staff costs; €30k for equipment
France - Agence Nationale de la Recherche (ANR)	Research Action COVID-19 (RA-COVID-19)		<p>Epidemiological studies</p> <p>Physiopathogenesis of the disease</p> <p>Infection prevention and control</p> <p>Ethics and social dynamics</p> <p>Global issues of the Covid-19 epidemic</p> <p>Post-COVID-19 healthcare innovations, including:</p>	10/28/2020	€ 150,000
Korea - Johnson & Johnson Innovation—JLABS, Seoul Metropolitan Government (“SMG”), Korea Health Industry Development Institute (“KHIDI”), Janssen Korea Ltd.	Seoul Innovation QuickFire Challenge: Healthcare for the New Normal https://jllabs.jnjinnovation.com/quickfire-challenges/seoul-innovation-quickfire-challenge-healthcare-new-normal		<p>Health technologies, including big data, artificial intelligence, and block chain</p> <p>E-health platforms that can improve the patient journey, empowering decision making for physicians and leading to better patient outcomes</p> <p>Rapid diagnostics for early detection and monitoring of rare diseases – in particular for pulmonary hypertension (PH)</p> <p>Companion diagnostics for oncology</p> <p>Smart systems for vaccine distribution and patient adherence</p>	8/31/2020	Prizes of KRW 150,000,000 (approximately \$125,000 USD) will be awarded

Funding Agency	Funding Opportunity	Solicitation Link	Topics	Due Date	Budget
Germany - Merck KGaA	Research Grant for Pandemic Preparedness		<p>Pre-outbreak R&D Preparedness for pandemic disease:</p> <p>Assessing the priority of pathogens and diseases with epidemic threat Platform technologies to accelerate the development of vaccines, drugs, diagnostics, vector control tools and delivery systems needed to control emerging health threats Innovative technologies for better personal protection equipment for infection control Response during outbreak:</p> <p>Novel health technologies (e.g. AI, bioelectronics, diagnostics) for early screening of potential infected patients and treatment facilitation. Fast-track identifying, testing and production of effective drugs and vaccines during outbreak</p>	Applications will be reviewed on a rolling basis	€500,000 per year
Germany - Federal Ministry of Education and Research	No current opportunities				
Germany - Deutsche Forschungsgemeinschaft (German Research Foundation)		https://www.dfg.de/en/research_funding/announcements_proposals/2020/information_sciences_20_20/index.html	Prevention, early detection, containment and investigation of the causes, impacts and management of epidemics and pandemics	Letter of Intent – Full Proposal – 9/1/2020	Not Specified
India	No current opportunities				
Japan	No current opportunities				

Funding Agency	Funding Opportunity	Solicitation Link	Topics	Due Date	Budget
Malta - Malta Council for Science and Technology and Malta Enterprise Corporation	COVID-19 R&D Fund		<p>Relevant medicinal products (including vaccines) and treatments, their intermediates, active pharmaceutical ingredients and raw materials</p> <p>Medical devices, hospital and medical equipment (including ventilators and protective clothing and equipment as well as diagnostic tools) and necessary raw materials</p> <p>Disinfectants and their intermediary products and raw chemical materials necessary for their production</p> <p>Data collection and processing tools related to innovative and/or improved approaches with regards to current and/or future infectious disease prevention; o trajectory of the epidemic/pandemic disease</p> <p>Better dissemination of recommendations by national (Public Health) and/or international health authorities (WHO)</p> <p>Any other research related to infectious diseases that can lead to epidemics in humans</p>	Applications are accepted on a rolling basis until 11/30/2020.	Not specified

Funding Agency	Funding Opportunity	Solicitation Link	Topics	Due Date	Budget
Spain - Fundación MAPFRE (MAPFRE Foundation)	Ignacio H. de Larramendi Research Grants		<p>The main topics are</p> <p>Strategies for habit change: prevention of obesity and promotion of physical activity. Patient education. Physical injury assessment. Health management: clinical quality and safety</p> <p>However, special attention will be given to projects that incorporate aspects related to COVID-19, such as infection reduction, self-care and the culture of self-protection, the relationship between previous health status (lifestyle) and morbimortality, COVID-19 and mental health, etc</p>	10/30/2020	30,000 Euros
Spain - Ministry of Science and Innovation	Solicitud Urgente de Expresiones de Interés para la Financiación Extraordinaria de Proyectos de Investigación sobre el SARS-CoV-2 y la Enfermedad COVID-19 (Spanish)		<p>Scalable rapid diagnostic techniques for SARS-CoV-2, especially related to early stage detection and healthcare stratification</p> <p>Clinical, biological, and molecular characteristics of COVID-19</p> <p>Therapeutic development, including pharmaceutical and non-pharmaceutical measures</p> <p>Antiviral resistance studies</p> <p>Vaccine development</p> <p>Socioeconomic impact of COVID-19</p> <p>Integrated epidemiological controls, including AI and Big Data</p>	Ongoing	Not Specified; Total Program Budget €24,000,000
Sweden - Vinnova	Innovations to mitigate the crisis: Finding new ways in the time of a crisis		<p>Any new coronavirus-related need addressed through the conversion of production or activities, where a first solution is ready within 6-12 months</p>	8/21/2020	Up to SEK 1,000,000
United Kingdom					